Department of Women's and Children's Health, Uppsala University, Sweden.
Acta Obstet Gynecol Scand. 2012 Apr;91(4):420-7. doi: 10.1111/j.1600-0412.2011.01333.x. Epub 2012 Jan 19.
In spite of combined oral contraceptives (COCs) having been available for more than 50 years, surprisingly little is known about the prevalence of truly COC-related adverse mood symptoms and about the underlying biological mechanisms of proposed changes in mood and affect. Precise estimates of COC-related adverse mood symptoms are not available due to the lack of placebo-controlled trials. In prospective trials the frequency of women who report deteriorated mood or deteriorated emotional well-being varies between 4 and 10%, but it can be assumed that the causal relation in these prevalence rates is overestimated. Adverse mood symptoms and somatic symptoms are most pronounced during the pill-free interval of the treatment cycles, but whether extended COC regimens would be more favorable in this respect is not known. COCs with anti-androgenic progestagens, such as drospirenone and desogestrel, appear more favorable in terms of mood symptoms than progestagens with a more androgenic profile. Available data suggest that lower doses of ethinylestradiol could be beneficial.
尽管复方口服避孕药(COC)已经问世超过 50 年,但人们对真正与 COC 相关的不良情绪症状的流行程度以及情绪和情感变化的潜在生物学机制知之甚少。由于缺乏安慰剂对照试验,因此无法获得确切的 COC 相关不良情绪症状的估计值。在前瞻性试验中,报告情绪恶化或情绪健康恶化的女性频率在 4%至 10%之间,但可以假设这些流行率中的因果关系被高估了。在治疗周期的无药丸间隔期间,不良情绪症状和躯体症状最为明显,但延长 COC 治疗方案在这方面是否更有利尚不清楚。具有抗雄激素孕激素特性的 COC,如屈螺酮和去氧孕烯,在情绪症状方面似乎比具有更多雄激素特性的孕激素更有利。现有数据表明,低剂量的炔雌醇可能有益。